Study: NCT06507644

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: light curettage
Description: Before the treatment, the treated area will be degreased with 0.2% aqueous chlorhexidine. Next, a light curettage will be performed on the face with a sterile curette.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: light curettage
Description: Before the treatment, the treated area will be degreased with 0.2% aqueous chlorhexidine. Next, a light curettage will be performed on the face with a sterile curette.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: light curettage
Description: Before the treatment, the treated area will be degreased with 0.2% aqueous chlorhexidine. Next, a light curettage will be performed on the face with a sterile curette.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: light curettage
Description: Before the treatment, the treated area will be degreased with 0.2% aqueous chlorhexidine. Next, a light curettage will be performed on the face with a sterile curette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre irradiation of 1 hour
Description: A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 1 hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre irradiation of 1 hour
Description: A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 1 hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre irradiation of 3 hour
Description: A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 3 hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre irradiation of 3 hour
Description: A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 3 hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical application of 8% methyl aminolevulinate photosensitizer MAL
Description: Participants will be treated with 8% topical MAL photosensitizer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical application of 8% methyl aminolevulinate photosensitizer MAL
Description: Participants will be treated with 8% topical MAL photosensitizer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: topical application of 16% methyl aminolevulinate photosensitizer (MAL)
Description: Participants will be treated with 16% topical MAL photosensitizer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical application of 16% methyl aminolevulinate photosensitizer (MAL)
Description: Participants will be treated with 16% topical MAL photosensitizer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visible light source
Description: Skin illumination will be performed using a visible light source (LED) with a wavelength of 643 nm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visible light source
Description: Skin illumination will be performed using a visible light source (LED) with a wavelength of 643 nm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visible light source
Description: Skin illumination will be performed using a visible light source (LED) with a wavelength of 643 nm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visible light source
Description: Skin illumination will be performed using a visible light source (LED) with a wavelength of 643 nm